Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors

NCT04794699 is registered in ClinicalTrials.gov with IDEAYA Biosciences as lead sponsor.

NCT NCT04794699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04794699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors
Lead sponsor
IDEAYA Biosciences
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 14, 2021
Completion date
February 4, 2027
Enrollment
169 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor